Vinten-Johansen J, Zhao Z-Q, Zatta A J, Kin H, Halkos M E, Kerendi F
The Cardiothoracic Research Laboratory, Carlyle Fraser Heart Center, 550 Peachtree Street N.E., Atlanta, Georgia 30308-2225, USA.
Basic Res Cardiol. 2005 Jul;100(4):295-310. doi: 10.1007/s00395-005-0523-x. Epub 2005 Mar 30.
Reperfusion injury is a complex process involving several cell types (endothelial cells, neutrophils, and cardiomyocytes), soluble proinflammatory mediators, oxidants, ionic and metabolic dyshomeostasis, and cellular and molecular signals. These participants in the pathobiology of reperfusion injury are not mutually exclusive. Some of these events take place during the very early moments of reperfusion, while others, seemingly triggered in part by the early events, are activated within a later timeframe. Postconditioning is a series of brief mechanical interruptions of reperfusion following a specific prescribed algorithm applied at the very onset of reperfusion. This algorithm lasts only from 1 to 3 minutes depending on species. Although associated with re-occlusion of the coronary artery or re-imposition of hypoxia in cell culture, the reference to ischemia has been dropped. Postconditioning has been observed to reduce infarct size and apoptosis as the "end games" in myocardial therapeutics; salvage of infarct size was similar to that achieved by the gold standard of protection, ischemic preconditioning. The cardioprotection was also associated with a reduction in: endothelial cell activation and dysfunction, tissue superoxide anion generation, neutrophil activation and accumulation in reperfused myocardium, microvascular injury, tissue edema, intracellular and mitochondrial calcium accumulation. Postconditioning sets in motion triggers and signals that are functionally related to reduced cell death. Adenosine has been implicated in the cardioprotection of postconditioning, as has e-NOS, nitric oxide and guanylyl cyclase, opening of K(ATP) channels and closing of the mitochondrial permeability transition pore. Cardioprotection by postconditioning has also been associated with the activation of intracellular survival pathways such as ERK1/2 and PI3 kinase - Akt pathways. Other pathways have yet to be identified. Although many of the pathways involved in postconditioning have also been identified in ischemic preconditioning, some may not be involved in preconditioning (ERK1/2). The timing of action of these pathways and other mediators of protection in postconditioning differs from that of preconditioning. In contrast to preconditioning, which requires a foreknowledge of the ischemic event, postconditioning can be applied at the onset of reperfusion at the point of clinical service, i.e. angioplasty, cardiac surgery, transplantation.
再灌注损伤是一个复杂的过程,涉及多种细胞类型(内皮细胞、中性粒细胞和心肌细胞)、可溶性促炎介质、氧化剂、离子和代谢紊乱以及细胞和分子信号。这些参与再灌注损伤病理生物学过程的因素并非相互排斥。其中一些事件发生在再灌注的最初时刻,而其他一些事件似乎部分由早期事件触发,在较晚的时间范围内被激活。后处理是在再灌注开始时按照特定规定算法进行的一系列短暂的再灌注机械中断。根据物种不同,该算法仅持续1至3分钟。尽管与冠状动脉再闭塞或细胞培养中再次施加缺氧有关,但现在已不再提及缺血。后处理已被观察到可减少梗死面积和凋亡,这是心肌治疗中的“最终目标”;梗死面积的挽救与保护的金标准——缺血预处理所达到的效果相似。心脏保护还与以下方面的减少有关:内皮细胞激活和功能障碍、组织超氧阴离子生成、中性粒细胞激活和在再灌注心肌中的积聚、微血管损伤、组织水肿、细胞内和线粒体钙积聚。后处理启动了与减少细胞死亡功能相关的触发因素和信号。腺苷与后处理的心脏保护作用有关,内皮型一氧化氮合酶、一氧化氮和鸟苷酸环化酶、ATP敏感性钾通道开放以及线粒体通透性转换孔关闭也与之有关。后处理的心脏保护作用还与细胞内生存途径(如ERK1/2和PI3激酶 - Akt途径)的激活有关。其他途径尚未确定。尽管后处理中涉及的许多途径也在缺血预处理中被发现,但有些可能不参与预处理(ERK1/2)。这些途径和后处理中其他保护介质的作用时机与预处理不同。与需要预知缺血事件的预处理不同,后处理可以在临床治疗时再灌注开始时应用,即血管成形术、心脏手术、移植时。